Matsuo Yukiko, Matsumoto Kenya, Inaba Niro, Mimaki Yoshihiro
Tokyo University of Pharmacy and Life Sciences, School of Pharmacy.
Biol Pharm Bull. 2018;41(9):1485-1488. doi: 10.1248/bpb.b18-00324.
Daisaikoto Extract, a Kampo medicine listed in the Japanese pharmacopoeia 17th edition, is clinically used to treat obesity and related symptoms. Lipid metabolism is closely related to obesity, and pancreatic lipase inhibitors are therefore regarded as effective for the treatment of obesity. Although Daisaikoto has shown promise in the treatment of obesity, its mechanism of action has yet to be elucidated. In the present study, we found that Daisaikoto extract inhibits pancreatic lipase activity in a dose-dependent manner and decreases serum triglyceride levels in mice. To determine the crude drugs responsible for lipase inhibition, 8 variants of Daisaikoto extract without one crude drug were prepared and evaluated for lipase inhibitory activity. The lipase inhibitory activity of the Daisaikoto extract was reduced by excluding Scutellariae Radix (SR), which was found to inhibit lipase activity with an IC value of 1.70 mg/mL. In conclusion, Daisaikoto represents a natural medicine, in particular SR, capable of inhibiting pancreatic lipase and lipid absorption.
大柴胡汤提取物是日本第17版药典收录的一种汉方药物，临床上用于治疗肥胖及相关症状。脂质代谢与肥胖密切相关，因此胰脂肪酶抑制剂被认为对肥胖治疗有效。尽管大柴胡汤在肥胖治疗方面已显示出前景，但其作用机制尚未阐明。在本研究中，我们发现大柴胡汤提取物以剂量依赖方式抑制胰脂肪酶活性，并降低小鼠血清甘油三酯水平。为确定负责脂肪酶抑制的生药，制备了8种不含一种生药的大柴胡汤提取物变体，并评估其脂肪酶抑制活性。通过排除黄芩（SR），大柴胡汤提取物的脂肪酶抑制活性降低，发现SR以1.70mg/mL的IC值抑制脂肪酶活性。总之，大柴胡汤是一种天然药物，尤其是黄芩，能够抑制胰脂肪酶和脂质吸收。
